Promising Outlook for 4D Molecular Therapeutics: Buy Rating Backed by Strategic Partnerships and Strong Financial Position
I'm PortAI, I can summarize articles.
4D Molecular Therapeutics received a Buy rating from analyst Matthew Caufield of H.C. Wainwright, with a price target of $36.00. The rating is supported by positive data from the Phase 1/2 PRISM trial of its gene therapy candidate, 4D-150, and a strategic partnership with Otsuka Pharmaceutical, which provided $85 million upfront. The company also secured an $11 million investment from the CF Foundation and completed a $93 million equity offering, ensuring a strong financial position to support its pipeline.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments